Home » Stocks » NERV

Minerva Neurosciences, Inc. (NERV)

Stock Price: $1.84 USD -0.03 (-1.60%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $1.86 +0.02 (1.09%) Jul 30, 7:51 PM
Market Cap 78.61M
Revenue (ttm) 41.18M
Net Income (ttm) 5.29M
Shares Out 42.72M
EPS (ttm) 0.13
PE Ratio 14.49
Forward PE 11.21
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $1.84
Previous Close $1.87
Change ($) -0.03
Change (%) -1.60%
Day's Open 1.85
Day's Range 1.83 - 1.89
Day's Volume 214,120
52-Week Range 1.80 - 4.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago - Zacks Investment Research

Management to host conference call Management to host conference call

6 days ago - GlobeNewsWire

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Other stocks mentioned: BIIB, SAGE, VTGN
1 month ago - Zacks Investment Research

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...

1 month ago - GlobeNewsWire

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centra...

2 months ago - GlobeNewsWire

Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

2 months ago - Zacks Investment Research

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?

Other stocks mentioned: CYRN, OPK, WTRH
2 months ago - PennyStocks

Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: EVFM, NOVN, OBLN
2 months ago - PennyStocks

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boos...

2 months ago - Zacks Investment Research

Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, impr...

2 months ago - GlobeNewsWire

WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous s...

2 months ago - GlobeNewsWire

Management to host conference call Management to host conference call

2 months ago - GlobeNewsWire

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021

4 months ago - GlobeNewsWire

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva...

5 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) betwe...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - February 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - February 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...

5 months ago - Newsfile Corp

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...

5 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 5, 2021) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" ...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

5 months ago - Newsfile Corp

Boston, Massachusetts--(Newsfile Corp. - February 3, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Minerva Neurosciences, Inc. (NASDAQ: NER...

5 months ago - Newsfile Corp

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class a...

5 months ago - GlobeNewsWire

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...

5 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...

5 months ago - Newsfile Corp

Click here to join the case

5 months ago - GlobeNewsWire

NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV) and certain of ...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

6 months ago - Newsfile Corp

BOSTON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of share...

6 months ago - GlobeNewsWire

NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

6 months ago - GlobeNewsWire

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...

6 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 23, 2021) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between M...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

6 months ago - Newsfile Corp

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and Nov...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

6 months ago - Newsfile Corp

NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

6 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 19, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

6 months ago - Newsfile Corp

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, CYAD, GRTS, MRUS, TENX
6 months ago - Benzinga

NEW YORK, NY / ACCESSWIRE / January 19, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...

Other stocks mentioned: BRY, OTGLY
6 months ago - Accesswire

NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...

6 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

6 months ago - Newsfile Corp

NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...

Other stocks mentioned: BSX, KNDI
6 months ago - Accesswire

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma C... [Read more...]

Industry
Biotechnology
IPO Date
Jul 1, 2014
CEO
Remy Luthringer
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
NERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 280.43% from the latest price.

Price Target
$7.00
(280.43% upside)
Analyst Consensus: Buy